IP Library › Granted Patent US 12,427,164
Granted Patent B2
US 12,427,164 · App. 17/936,820 · Granted Sep 30, 2025

Microrna and uses thereof in prevention and/or treatment of fibroplasia medical sign and/or syndrome

Inventors: Chengyu Jiang (Beijing, CN); Jianchao Du (Beijing, CN); Zhu Liang (Beijing, CN); Jiantao Xu (Beijing, CN); Yan Zhao (Beijing, CN)
Assignee: BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD
A61K31/7105C12N15/102C12N15/113C12N15/63C12N2310/11C12N2310/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,427,164
App. No.
17/936,820
Granted
Sep 30, 2025
Kind
B2
Abstract

Provided are microRNA from a rhodiola root and uses thereof in the prevention and/or the treatment of a fibroplasia medical sign and/or syndrome.

Claims (6)

1. A method of treating a fibrotic disease and/or syndrome comprising administering to a subject in need thereof a polynucleotide, wherein the polynucleotide comprises a sequence set forth in SEQ ID NO: 11 and wherein the fibrotic disease and/or syndrome is a fibrotic disease and/or syndrome of lung.

2. The method according to claim 1 , wherein the fibrotic disease and/or syndrome is selected from the group consisting of:

silicosis, asbestosis, anthracosis, farmer's lung, air-conditioner lung, pigeon-breeder's lung, bagassosis and familial pulmonary fibrosis.

3. The method according to claim 1 , further comprising administering an additional anti-fibrotic agent separately and/or together, temporally and/or spatially, to the subject in need thereof, wherein the additional anti-fibrotic agent is an agent for treating the fibrotic disease/syndrome of lung.

4. The method according to claim 3 , wherein the additional anti-fibrotic agent is one or more selected from the group consisting of: a glucocorticoid, an immunosuppressive agent, an antioxidant, an anticoagulant, colchicine, interferon, ACEI and a statin.

5. The method according to claim 1 , wherein the polynucleotide is synthetic or expressed from an artificial vector.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE FROM BEIJJNG BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD TO BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD PREVIOUSLY RECORDED ON REEL 70075 FRAME 544. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 10, 2025
From: INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES
To: BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD
Reel/Frame 070171/0556 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2025
From: INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES
To: BEIJJNG BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD
Reel/Frame 070075/0544 →
Priority Claims (1)
CN 201710219899.X · Mar 29, 2017 · national
Continuity (2)
Division 16498435
Related Publication 20230293570A1 · Sep 21, 2023
References Cited (32)
US 20060045925A1 · Hsu · 2006 [cited by applicant]
US 20090293148A1 · Ren et al. · 2009 [cited by applicant]
US 20140363469A1 · Meyers et al. · 2014 [cited by applicant]
US 20150121569A1 · Combier et al. · 2015 [cited by applicant]
US 20180273941A1 · Mao et al. · 2018 [cited by applicant]
CN 103627705 · 2014 [cited by applicant]
CN 103800698 · 2014 [cited by applicant]
CN 104147022 · 2014 [cited by applicant]
JP 2005511551 · 2005 [cited by applicant]
KR 20120092541 · 2012 [cited by applicant]
WO WO2005024061 · 2005 [cited by applicant]
WO WO2008112283A2 · 2008 [cited by applicant]
WO WO2013109604 · 2013 [cited by applicant]
WO WO2014026333 · 2014 [cited by applicant]
WO WO2015166060 · 2015 [cited by applicant]
WO WO2016065349 · 2016 [cited by applicant]
Pollard, Kenneth Michael. “Silica, silicosis, and autoimmunity.” Frontiers in immunology 7 (2016): 97. [cited by examiner]
Leung, Chi Chiu, Ignatius Tak Sun Yu, and Weihong Chen. “Silicosis.” The Lancet 379.9830 (2012): 2008-2018. [cited by examiner]
Babalola et al., “The role of microRNAs in skin fibrosis,” [cited by applicant]
Brennan et al., “Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1,” [cited by applicant]
Chen et al., “Expression of antisense of microRNA-26a-5p in mesenchymal stem cells increases their therapeutic effects against cirrhosis,” [cited by applicant]
English translation of PCT International Search Report issued in International Application No. PCT/CN2017/078815, dated Jan. 5, 2018. [cited by applicant]
Extended European Search Report issued in European Patent Application No. 17903508.4, dated Dec. 8, 2020. [cited by applicant]
Kropski, J. A. et al.,“The genetic basis of idiopathic pulmonary fibrosis,” [cited by applicant]
Lyson et al., “MicroRNAs support a turtle + lizard clade,” [cited by applicant]
Mu et al., “MicroRNA-143-3p inhibits hyperplastic scar formation by targeting connecdtive tissue growth factor CTGF/CCN2 via the Akt/tmTOR pathway,” [cited by applicant]
Office Communication issued in correspondence Japanese Application No. 2021-160557 dated Sep. 20, 2022 { English translation}. [cited by applicant]
Van Rooij et al., “Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis,” [cited by applicant]
Wang et al., “Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal Fibrosis,” [cited by applicant]
Yang et al., “Genome-wide analyses of amphioxus microRNAs reveal an immune regulation via miR-92d targeting C3,” [cited by applicant]
Zhang et al., “Identification and developmental profiling of conserved and novel microRNAs in [cited by applicant]
Office Action issued in Japanese Patent Application No. 2023-206389, dated Dec. 3, 2024. [cited by applicant]